The findings of a new study highlight the potential of a drug called lenacapavir as a revolutionary HIV prevention method.
In Short
- Lenacapavir demonstrated 100% efficacy in preventing HIV infections during a Phase 3 trial
- The trial involved over 5,000 HIV-negative women and adolescent girls in Africa
- Lenacapavir could offer a highly effective, tolerable, and discreet choice for HIV prevention if approved
A study has found that two shots a year of a drug currently used to treat HIV were highly effective at preventing infections among young women and adolescent girls in Africa.
The drug, lenacapavir, demonstrated 100% efficacy in preventing HIV infections during a Phase 3 trial, according to data released by drugmaker Gilead and published in the New England Journal of Medicine.
